Alembic Pharma receives USFDA approval for Clonazepam

Alembic Pharmaceuticals has received USFDA approval for Clonazepam orally disintegrating tablets which are used for treatment of seizures, adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures .

The approved drug is therapeutically equivalent to Klonopin produced by Hoffmann-La Roche, Inc. The drug will be produced in strengths of 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg. According to market estimates, Clonazepam orally disintegrating tablets USP has an estimated market size of USD 20 million for 12 months ending December 2018.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.